MYL(600993) 证券时报网·2025-04-02 14:57Core Insights - The company reported a revenue of 3.728 billion yuan for 2024, representing a year-on-year growth of 18.85% [1] - Net profit attributable to shareholders reached 528 million yuan, up 19.14% year-on-year, with a net profit of 511 million yuan after deducting non-recurring gains, showing a significant increase of 44.98% [1] - The company plans to distribute a cash dividend of 6.2 yuan per 10 shares, with a payout ratio exceeding 50% [1] Financial Performance - Revenue growth was driven by a focus on enhancing retail terminal sales and expanding head chain partnerships, with a notable increase in the contribution from top chain outputs [1] - The company achieved a 19.91% year-on-year increase in revenue from the parent company, with a 23.19% growth in hemorrhoid treatment products [1] Product and Market Expansion - The company has successfully launched a series of health wet wipes, achieving annual sales exceeding 100 million yuan [1] - The beauty product line saw a revenue increase of 30% year-on-year, indicating a strong performance in the eye health segment [1] Technological Advancements - The integration of 5G and AI technologies has led to a 60% increase in production capacity and a 30% improvement in efficiency at the company's smart factory [2] - The production process for ointments and suppositories is now 100% automated and digitally managed, establishing a leading position in the industry [2] Smart Manufacturing and Logistics - The establishment of the "MAYINGLONG Industrial Intelligent Connection Platform" has enabled data interconnectivity across 12 categories, reducing product delivery cycles by over 50% [3] - The implementation of smart logistics solutions, including AGV vehicles and RFID technology, has facilitated real-time synchronization of information and physical flows during product transfers [2][3] Sustainability Initiatives - The company has been recognized with titles such as "Green Manufacturing" and "National Green Factory," reflecting its commitment to sustainable practices [3] - Continuous publication of ESG reports has positioned the company among the top 20 in the ESG pharmaceutical sector [3]